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ABSTRACT
Background: Renal sympathetic denervation (RSD) is a prom-
ising strategy in the treatment of resistant hypertension. No 
studies have assessed the effect of RSD on quality of life in 
our country, which was the aim of this study. Methods: The 
EuroQol 5 Dimensions questionnaire (EQ 5D 5L) was chosen to 
evaluate quality of life in 10 patients undergoing RSD, and it 
was applied before and 3 months after the procedure. Results: 
Mean age was 47.3 ± 12 years and 90% of the patients were 
female. Baseline blood pressure was 187 ± 37.5/104 ± 18.5 
mmHg and the number  of antihypertensive drugs was 7.6 
± 1.3. Before the procedure, the value assigned to health 
status was 37.5 ± 22.7, increasing at 3 months  to 70.5 ± 
20.9 (P = 0.01). In the follow- up, in addition to a decrease 
in the number of antihypertensive drugs (7.6 ± 1.3 vs. 6 ± 
2.2; P = 0.05), a trend towards reduced levels of systolic 
blood pressure (187 ± 36 mmHg vs 170 ± 44 mmHg; P = 
0.10) and  diastolic blood pressure (104 ± 18 mmHg vs 98 ± 
20 mmHg; P = 0.20) was observed. Health status improvement 
resulted from a reduction of problems related to mobility, 
usual activities, pain/discomfort and anxiety/depression. The 
magnitude of blood pressure reduction was not associated with 
improved quality in all of the patients. On the other hand, 
those who had a decrease in the number of antihypertensive 
drugs reported a better health  status. Conclusions: Patients 
with resistant hypertension have poor health status scores. RSD 
improved quality of life in most patients. Further studies are 
required to confirm consistent benefits.
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RESUMO
Denervação Simpática Renal e Qualidade de Vida
Introdução: A denervação simpática renal (DSR) é estratégia 
promissora no tratamento da hipertensão arterial resistente. 
Nenhum estudo avaliou o efeito da DSR na qualidade de vida 
em nosso meio, objetivo deste estudo. Métodos: O questionário 
EuroQol-5 Dimensions (EQ 5D 5L) foi utilizado para avaliar a 
qualidade de vida de 10 pacientes submetidos a DSR, sendo 
aplicado antes e 3 meses após o procedimento. Resultados: A 
média de idade foi de 47,3 ± 12 anos e 90% dos pacientes 
eram do sexo feminino. A pressão arterial basal foi de 187 
± 37,5/104 ± 18,5 mmHg e o número de anti hipertensivos 
utilizados foi de 7,6 ± 1,3. Antes do procedimento, o valor 
atribuído ao estado de saúde foi de 37,5 ± 22,7, aumentando 
aos 3 meses para 70,5 ± 20,9 (P = 0,01). No seguimento, além 
da diminuição do número de anti hipertensivos (7,6 ± 1,3 vs. 
6 ± 2,2; P = 0,05), foi observada tendência a queda dos níveis 
da pressão sistólica (187 ± 36 mmHg vs. 170 ± 44 mmHg; 
P = 0,10) e da pressão diastólica (104 ± 18 mmHg vs. 98 ± 
20 mmHg; P = 0,20). A melhora do estado de saúde resultou 
da redução de problemas relacionados a mobilidade, atividades 
usuais, dor/desconforto e ansiedade/depressão. A magnitude 
da redução da pressão arterial não se associou à melhora 
da qualidade de vida em todos os pacientes. Por outro lado, 
aqueles que experimentaram redução do número de anti-
hipertensivos relataram melhor estado de saúde. Conclusões: 
Hipertensos resistentes apresentam baixos escores de estado 
de saúde. A DSR apontou melhora da qualidade de vida na 
maioria dos pacientes. Estudos maiores são necessários para 
confirmar benefícios consistentes.
DESCRITORES: Hipertensão. Rins. Simpatectomia. Qualidade 
de vida.
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The prevalence of resistant hypertension ranges from 10% to 15%, depending on the population studied and the applied definitions. Higher figures are observed 
in conditions associated with sympathetic hyperacti vity, 
such as obesity, obstructive sleep apnea, diabetes, and 
renal dysfunction. Chronic arterial hypertension is asso-
ciated with a substantial risk of stroke, coronary artery 
disease, and vascular disorders. In patients aged 40 to 
70 years, each increment of 20 mmHg in systolic blood 
pressure or of 10  mmHg in diastolic blood pressure 
doubles the risk of cardiovascular disease in the range 
of blood pressure values between 115/75  mmHg and 
185/115  mmHg.1 Studies indicate that hypertension is 
associated with worse quality of life.2,3
Recently, the Symplicity-HTN2 Trial study demon-
strated significant reduction in blood pressure (BP) in 
drug-resistant hypertensive patients submitted to renal 
sympathetic denervation.4 However, data regarding the 
safety, long-term effectiveness, reduction in the number 
of antihypertensive drugs, cost-effectiveness ratio, and 
effects on quality of life were not evaluated, especially 
in the Brazilian population. This study aimed to evalu-
ate the effects of the experience with renal sympathetic 
denervation on the quality of life in patients with drug-
resistant hypertension in a tertiary center.
Methods
Population
The study included patients submitted to renal 
sympathetic denervation who met the inclusion 
criteria: age between 18 and 80 years; systolic 
blood pressure measured at the clinic > 160 mmHg 
despite treatment with at least three antihypertensive 
drugs; blood pressure controlled with at least four 
antihypertensive drugs; and favorable anatomy to 
renal sympathetic denervation determined by renal 
angiography. Exclusion criteria were: secondary 
hypertension; creatinine clearance <  45  mL/min; 
severe liver disease; New York Heart Association 
(NYHA) functional class III-IV heart failure or ejec-
tion fraction <  35%; renal artery anomalies, such 
as stenos is >  50%, presence of stent, or previous 
angioplasty; renal artery diameter <  4  mm, and/or 
length < 20 mm; pregnancy; life expectancy < 1 year; 
or inability to complete follow-up requirements. An 
informed consent was obtained in all cases, and the 
study was approved by the local ethics committee.
euroQol-5 dimensions Questionnaire
The EuroQol-5 Dimensions (EQ 5D 5L), a ques-
tionnaire developed by the EuroQol group, aims at 
assessing health status, in a simple and generic way, 
and thus helping in the clinical assessment and imple-
mentation of economic measures.5 Applicable to a wide 
variety of health conditions, the EQ-5D-5L does not 
require a high cognitive level and can be performed 
in a few minutes.
The tool considers each domain independently 
and does not produce a total score of quality of life, 
considering the premise that quality of life is a mul-
tidimensional construct. It consists of two pages and 
includes two main components: a descriptive system 
that defines the health-related quality of life (HRQoL) 
in five dimensions (mobility, self-care, usual activities, 
pain/discomfort, and anxiety/depression), each with five 
levels of severity (1, no problems; 2, some problems; 3, 
moderate problems; 4, severe problems; and 5, extreme 
problems), and a visual analog scale (VAS), in which 
patients indicate how they feel on a scale of 0 to 100, 
where 0 represents the worst imaginable and 100 the 
best imaginable health, and the value is written in a 
box placed next to the scale (Figure 1). Patients are 
then classified with distinct five-digit health codes.5 
For instance, state 11111 indicates no problems in 
any dimensions, whereas state 55555 shows extreme 
problems in all dimensions, and state 12345 shows 
no problems in mobility, some problems in self-care, 
moderate problems related to usual activities, severe 
problems regarding pain/discomfort, and extreme pro-
blems regarding anxiety/depression.
statistical Analysis
Continuous variables were described as mean 
and standard deviation, and categorical variables as 
absolute and relative frequencies. The comparison of 
continuous variables was performed by paired Student’s 
t-test, considering the pre- and post-procedure values. 
P-values < 0.05 were considered statistically significant. 
STATA 11 SE software was used for statistical analysis 
and chart construction.
Results
In total, ten patients (age 47.3 ± 12 years, 90% 
women) underwent renal sympathetic denervation at 
the Instituto Dante Pazzanese de Cardiologia (São 
Paulo, SP, Brazil) between July and November 2012. 
Basal BP was 187 ± 37.5/104 ± 18.5  mmHg, and 
the mean number of antihypertensive drugs was 7.6 
± 1.3 (ranging from five to nine). The mean time of 
hypertension diagnosis was 18.3 ± 10.6 years. All 
patients completed the questionnaire prior to the 
procedure and at three months of follow-up. The 
questionnaire was administered in-person by a spe-
cialist in hypertension. At three months, there was 
a tendency of BP reduction: systolic blood pressure 
pre vs. Post (187 ± 36  mmHg vs. 170 ±  44  mmHg; 
P =  0.10), and diastolic blood pressure pre vs. post 
(104  ±  18  mmHg vs. 98 ± 20  mmHg; P = 0.20); a 
significant decrease in the number of antihypertensive 
drugs pre vs. post (7.6 ± 1.3 drugs vs. 6 ± 2.2 drugs; 
P = 0.05) was also observed. 
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Figure 1 – EuroQOL-5 Dimensions score. To the left, the descriptive system that defines the health-related quality of life in five dimensions (HRQoL) 
and to the right, the visual scale in which the patients indicate the perception of their health status (Visual Analog Scale – VAS).
Before and after the procedure, 20 different com-
binations of values assigned to the dimensions were 
obtained. No patients showed absence of problems in 
all dimensions, nor extreme problems with self-care, 
performing usual activities, or pain/discomfort. Of the 
five analysed dimensions, extreme problems were only 
observed regarding mobility and anxiety/depression, 
whereas self-care was reportedby most patients as cau-
sing noproblems. Two patients reported extreme anxiety 
or depression before the procedure, and in one, there 
was no improvement during follow-up. There was im-
provement in the degree of anxiety/depression in four 
patients, in four other patients this dimension remained 
unchanged, and two patients reported a worsening of 
the condition (Table 1).
Before the procedure, the mean subjective health 
status was 37.5 ± 22.7, with significant improvement at 
three months (70.5 ± 20.9; P = 0.01) (Figures 2 and 3). 
The health status improvement was the result of a decrease 
in problems related to the dimensions of mobility, usual 
activities, pain/discomfort, and anxiety/depression. The 
magnitude of the decrease in BP was not associated 
with an improvement in quality of life in all patients. 
Conversely, those who experienced reduction in the 
number of antihypertensive drugs reported improved 
health status after renal sympathetic denervation.
discussion
Renal sympathetic denervation was first employed 
in the treatment of resistant hypertension in the late 
1930s. The procedure consisted in splanchnicectomy 
with sympathectomy, both thoracic and lumbar, associa-
ted with celiac ganglionectomy. Despite the promising 
results, frequent and disabling adverse events such as 
orthostatic hypotension, sphincter incontinence, sexual 
dysfunction, and paroxysmal excessive sweating werethe 
main limitations of this strategy. Hoobler et al.6 and 
Smithwick and Thompson7 demonstrated significant re-
ductions in BP levels in up to 45% of patients between 
the first and fifth years post-sympathectomy. Hoobler 
et al.6 reported improvement of symptoms such as 
headache, dizziness, irritability, and nervousness that 
were disproportionate to the BP reduction, and satis-
faction was reported by 95% of patients submitted to 
the surgery. Crile8 demonstrated that, in addition to 
the effects on BP, celiac ganglionectomy is associated 
with reduction in nervousness, fatigue, and irritability 
in 78% of cases.
The results of the present study indicate that patients 
with drug-resistant hypertension have substantial reduc-
tion in quality of life. In this small series of cases, many 
aspects improved after renal sympathetic denervation, 
ANXIETY/DEPRESSION
I am not anxious or depressed
I am slightly anxious or depressed
I am moderately anxious or depressed
I am very anxious or depressed
I am extremely anxious or depressed
Under each heading, please tick the ONE box that best describes
your health TODAY.
The best health
you can imagine
The worst health
you can imagine
1. We like to know how is your health today.
2. This scale is marked from 0 to 100.
3. 100 means the best health you can imagine.
    0 means the worst health you can imagine.
4. Mark an X on the scale to indicate how is your 
    health today.
5. Now, please note the number you marked on the 
    scale in the box below.
MOBILITY
I have no problems in walking about
I have slight problems in walking about
I have moderate problems in walking about
I have severe problems in walking about
I am unable to walk about
SELF-CARE
I have no problems washing or dressing myself
I have slight problems washing or dressing myself 
I have moderate problems washing or dressing myself 
I have severe problems washing or dressing myself
I am unable to wash or dress myself
USUAL ACTIVITIES (e.g., work, study, housework, family or leisure activities)
I have no problems doing my usual activities
I have slight problems doing my usual activities
I have moderate problems doing my usual activities
I have severe problems doing my usual activities
I am unable to do my usual activities
PAIN/DISCOMFORT
I have no pain or discomfort
I have slight pain or discomfort
I have moderate pain or discomfort
I have severe pain or discomfort
I have extreme pain or discomfort
Your Health Today =
100
95
90
85
80
75
70
65
60
55
50
45
40
35
30
25
20
15
10
5
0
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denervation were assessed for quality of life through 
the SF36 questionnaire and the Beck Depression 
Inventory-II after three months of follow-up. These 
authors showed reductions of 16 ± 4 mmHg and 6 
± 2 mmHg in systolic and diastolic BP, respectively, 
and improved quality of life as a result of increased 
vitality, social function, and emotional and mental 
health, as well as reduced symptoms of sadness 
and fatigue, and improved libido. The magnitude 
of reduction in blood pressure levels was also not 
associated with changes in quality of life.9
In rats with chronic renal failure, afferent renal 
sympathetic denervation prevented the development 
of hypertension and elevation of norepinephrine in 
the posterior and lateral hypothalamic nuclei, and in 
the locus ceruleus.10 The highest concentration of 
norepinephrine is located in the locus ceruleus, 
such as reduction in problems related to mobility, 
usual activities, pain/discomfort, and anxiety/depres-
sion dimensions. It is noteworthy that the improvement 
in quality of life was not associated with the degree of 
improvement in BP levels in all patients. Conversely, those 
who experienced a decrease in the number of antihy-
pertensive drugs reported better health status. In spite of 
the small population sample, an absence of response to 
renal sympathetic denervation was observed in 20% of 
cases, which is consistent with literature data.2 The two 
patients who did not have a reduction in BP levels or 
the number of medications were those who maintained 
unchanged health status after renal sympathetic dener-
vation. One patient reported worsening of health status 
resulting from increased level of anxiety consequent 
to personal problems. The present results are similar 
to those observed in the study by Lambert et al.,9 in 
which 40 patients submitted to renal sympathetic 
Figure 2 – Comparison of the health status before and after renal sym-
pathetic denervation.The black lines correspond to the health status of 
each patient, and the red line represents the mean value.
Figure 3 – Box plot demonstrating statistically significant difference in 
health status before and after renal sympathetic denervation. EQ, EuroQol.
Table 1  
Proportion of patients before and after renal sympathetic denervation, for each dimension  
of the EQ-5D-5L questionnaire
Mobility
(%)
Self-care
(%)
Usual activities
(%)
Pain/discomfort
(%)
Anxiety/depression
(%)
Pre Post Pre Post Pre Post Pre Post Pre Post
No problem 0 20 70 70 20 40 20 20 10 10
Some problems 20 30 30 30 30 30 40 40 20 40
Moderate problems 50 20 0 0 40 10 10 30 30 10
Severe problems 20 20 0 0 10 20 30 10 20 30
Extreme problems 10 10 0 0 0 0 0 0 20 10
EQ-5D-5L, EuroQol 5 Dimensions.
Health status
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which, together with the hypothalamus, influences 
the behavioral responses.11,12 The biological effects of 
renal sympathetic denervation on quality of life, how-
ever, are still indeterminate and deserve further trials.
Despite not reaching statistical significance, probably 
due to the small number of patients and/or less marked 
decrease in blood pressure levels due to the con-
comitant decrease in the number of antihypertensive 
drugs, significant improvement of health status was 
observed, demonstrating that the benefits of renal 
sympathetic denervation may extend beyond blood 
pressure control.
study limitations
Some limitations should be noted. First, quality 
of life assessment is subjective and may indicate indi-
vidual opinions rather than the actual health status of 
the individual. Moreover, it can vary over time in the 
same patient, depending on the circumstances con-
cerned and priorities, which constitutes a limitation of 
questionnaires used to assess quality of life. Second, 
variables such as socioeconomic status, education, 
and age were not correlated to the findings and could 
have had an effect on the observed results. Third, the 
possible placebo effect of the procedure may confound 
result interpretation. Finally, the small sample size is 
an important limitation of this case series.
conclusion
In this small case series, it was observed that 
adults with resistant hypertension have low scores for 
health status and unsatisfactory quality of life for most 
domains of the EQ-5D-5L questionnaire. Comparison of 
outcomes after renal sympathetic denervation showed 
improvement in quality of life in most patients. Larger 
studies are required to confirm consistent benefits.
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